Skip to main content

Table 4 Subgroup analysis adjusted by the risk factors of prostate cancer prevalence

From: The effect of subsequent immunosuppressant use in organ-transplanted patients on prostate cancer incidence: a retrospective analysis using the Korean National Health Insurance Database

Characteristics N Event Duration IR (per 1000) Model 1 Model 2 Model 3
HR p value HR p value HR p value
Transplantation           
 No transplantation 38,910 111 190,764.2 0.58187 1 (Ref.)  < .001 1 (Ref.)  < 0.001 1 (Ref.) 0.1948
 Transplantation 12,970 77 61,331.36 1.25548 2.178 (1.628,2.912) 1.965 (1.392,2.772) 0.539 (0.212,1.372)    
Transplanted organ           
 Control 38,910 111 190,764.2 0.58187 1 (Ref.)  < .001 1 (Ref.)  < 0.001 1 (Ref.) 0.0229
 1. Kidney 7026 21 33,615.34 0.62471 1.08 (0.677,1.722) 1.066 (0.629,1.806) 0.28 (0.102,0.767)    
 2. Liver 5445 54 25,616.58 2.10801 3.661 (2.645,5.068) 2.716 (1.876,3.931) 0.729 (0.29,1.832)    
 3. Pancreas 28 0 105.38 0 N.A   N.A   N.A  
 4. Heart 398 2 1760.07 1.13632 2.013 (0.497,8.151) 1.241 (0.297,5.179) 0.327 (0.062,1.73)    
 5. Lung 73 0 233.99 0 N.A   N.A   N.A  
  1. Model 1 Rude
  2. Model 2 Adjusted by the “Age, Aspirin, Statin, Hypertension, Diabetes, Dyslipidemia”
  3. Model 3 Adjusted by the “Age, Aspirin, Statin, Hypertension, Diabetes, Dyslipidemia, Immunosuppressant”